GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Purchase Of Business

Xbrane Biopharma AB (OSTO:XBRANE) Purchase Of Business : kr0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Purchase Of Business?

Xbrane Biopharma AB's purchase of business for the three months ended in Dec. 2023 was kr0.0 Mil. It means Xbrane Biopharma AB spent kr0.0 Mil on purchasing business. Xbrane Biopharma AB's purchase of business for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.0 Mil.

Compared with last quarter (kr0.0 Mil in Sep. 2023 ), Xbrane Biopharma AB spent the same money on purchasing business in Dec. 2023 (kr0.0 Mil).

Xbrane Biopharma AB Purchase Of Business Historical Data

The historical data trend for Xbrane Biopharma AB's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Purchase Of Business Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Purchase Of Business
Comparable Companies
OSTO:DMYD B OSTO:CANTA XSAT:CURAS OSTO:ONCO OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
7XB:Germany
Address
Retzius vag 8, Solna, SWE, 171 65
Website
https://www.xbrane.com
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines